Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Life Sci：KRas-ERK1 / 2信号的激活通过抑制赖氨酸16处组蛋白H4的乙酰化来驱动胶质瘤的发生发展

2019-04-22 不详 网络

关注

赖氨酸16（H4K16ac）上H4的乙酰化已被充分表征为乙酰化标记，其表达与人类癌症的肿瘤发生密切相关。本研究旨在揭示KRas突变是否通过调节H4乙酰化来驱动胶质瘤的发生和发展。通过蛋白质印迹分析测试用用于表达突变体KRas的质粒转染后人胶质母细胞瘤A172细胞中H4K16乙酰化的变化。进行MTT测定，transwell测定，软琼脂克隆形成测定，RT-PCR和染色质免疫沉淀以评估H4K16ac对A

赖氨酸16（H4K16ac）上H4的乙酰化已被充分表征为乙酰化标记，其表达与人类癌症的肿瘤发生密切相关。本研究旨在揭示KRas突变是否通过调节H4乙酰化来驱动胶质瘤的发生和发展。

通过蛋白质印迹分析测试用用于表达突变体KRas的质粒转染后人胶质母细胞瘤A172细胞中H4K16乙酰化的变化。进行MTT测定，transwell测定，软琼脂克隆形成测定，RT-PCR和染色质免疫沉淀以评估H4K16ac对A172细胞生长和迁移的影响。此外，通过RT-PCR和蛋白质印迹分析研究了参与H4K16ac脱乙酰化的酶。

结果显示，H4K16ac被KRas-ERK1/2活化脱乙酰化。H4K16Q（用于模拟H4K16ac的质粒）抑制A172细胞活力，集落形成和迁移能力。此外，H4K16ac能够调节几种ERK1/2通路下游基因的转录。KRas-ERK1/2信号通过调节组蛋白脱乙酰酶Sirt2以及组蛋白乙酰转移酶TIP60抑制K16处的H4乙酰化。此外，KRas-ERK1/2通过MDM2-dependnet方式抑制TIP60。

总之，我们的研究结果表明，KRas-ERK1/2信号的激活至少部分通过调节K16的H4乙酰化来参与胶质瘤的发生和发展。KRas-ERK1/2信号通过Tirt60的Sirt2和MDM2-依赖性变性介导H4K16的乙酰化。

原始出处：

Wei Y, Wang F, et al., Activation of KRas-ERK1/2 signaling drives the initiation and progression of glioma by suppressing the acetylation of histone H4 at lysine 16. Life Sci. 2019 Apr 1. pii: S0024-3205(19)30250-4. doi: 10.1016/j.lfs.2019.03.079. 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1752127, encodeId=3ce11e5212757, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sat Jul 20 11:57:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068592, encodeId=8fba206859295, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Apr 02 23:57:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030747, encodeId=003f2030e47c8, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Wed Oct 30 08:57:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365240, encodeId=36c43652400f, content=默默, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 15:59:35 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365202, encodeId=27ea365202b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Apr 24 23:03:08 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369007, encodeId=5f3e136900e0d, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384693, encodeId=91271384693e6, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592165, encodeId=1e6f1592165a0, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365088, encodeId=44af3650882e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Apr 22 20:23:08 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-07-20 chenlianhui

    #ERK#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1752127, encodeId=3ce11e5212757, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sat Jul 20 11:57:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068592, encodeId=8fba206859295, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Apr 02 23:57:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030747, encodeId=003f2030e47c8, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Wed Oct 30 08:57:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365240, encodeId=36c43652400f, content=默默, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 15:59:35 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365202, encodeId=27ea365202b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Apr 24 23:03:08 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369007, encodeId=5f3e136900e0d, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384693, encodeId=91271384693e6, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592165, encodeId=1e6f1592165a0, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365088, encodeId=44af3650882e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Apr 22 20:23:08 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2020-04-02 clmlylxy

    #Life#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1752127, encodeId=3ce11e5212757, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sat Jul 20 11:57:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068592, encodeId=8fba206859295, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Apr 02 23:57:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030747, encodeId=003f2030e47c8, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Wed Oct 30 08:57:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365240, encodeId=36c43652400f, content=默默, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 15:59:35 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365202, encodeId=27ea365202b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Apr 24 23:03:08 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369007, encodeId=5f3e136900e0d, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384693, encodeId=91271384693e6, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592165, encodeId=1e6f1592165a0, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365088, encodeId=44af3650882e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Apr 22 20:23:08 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-10-30 wgsun

    #发生发展#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1752127, encodeId=3ce11e5212757, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sat Jul 20 11:57:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068592, encodeId=8fba206859295, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Apr 02 23:57:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030747, encodeId=003f2030e47c8, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Wed Oct 30 08:57:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365240, encodeId=36c43652400f, content=默默, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 15:59:35 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365202, encodeId=27ea365202b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Apr 24 23:03:08 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369007, encodeId=5f3e136900e0d, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384693, encodeId=91271384693e6, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592165, encodeId=1e6f1592165a0, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365088, encodeId=44af3650882e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Apr 22 20:23:08 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-25 用户被禁用

    默默

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1752127, encodeId=3ce11e5212757, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sat Jul 20 11:57:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068592, encodeId=8fba206859295, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Apr 02 23:57:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030747, encodeId=003f2030e47c8, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Wed Oct 30 08:57:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365240, encodeId=36c43652400f, content=默默, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 15:59:35 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365202, encodeId=27ea365202b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Apr 24 23:03:08 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369007, encodeId=5f3e136900e0d, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384693, encodeId=91271384693e6, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592165, encodeId=1e6f1592165a0, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365088, encodeId=44af3650882e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Apr 22 20:23:08 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-24 医者仁心5538

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1752127, encodeId=3ce11e5212757, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sat Jul 20 11:57:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068592, encodeId=8fba206859295, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Apr 02 23:57:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030747, encodeId=003f2030e47c8, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Wed Oct 30 08:57:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365240, encodeId=36c43652400f, content=默默, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 15:59:35 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365202, encodeId=27ea365202b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Apr 24 23:03:08 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369007, encodeId=5f3e136900e0d, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384693, encodeId=91271384693e6, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592165, encodeId=1e6f1592165a0, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365088, encodeId=44af3650882e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Apr 22 20:23:08 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-24 yinhl1978

    #KRAS#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1752127, encodeId=3ce11e5212757, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sat Jul 20 11:57:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068592, encodeId=8fba206859295, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Apr 02 23:57:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030747, encodeId=003f2030e47c8, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Wed Oct 30 08:57:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365240, encodeId=36c43652400f, content=默默, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 15:59:35 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365202, encodeId=27ea365202b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Apr 24 23:03:08 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369007, encodeId=5f3e136900e0d, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384693, encodeId=91271384693e6, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592165, encodeId=1e6f1592165a0, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365088, encodeId=44af3650882e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Apr 22 20:23:08 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-24 xqptu

    #组蛋白#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1752127, encodeId=3ce11e5212757, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sat Jul 20 11:57:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068592, encodeId=8fba206859295, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Apr 02 23:57:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030747, encodeId=003f2030e47c8, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Wed Oct 30 08:57:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365240, encodeId=36c43652400f, content=默默, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 15:59:35 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365202, encodeId=27ea365202b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Apr 24 23:03:08 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369007, encodeId=5f3e136900e0d, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384693, encodeId=91271384693e6, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592165, encodeId=1e6f1592165a0, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365088, encodeId=44af3650882e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Apr 22 20:23:08 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-24 w363522455

    #赖氨酸#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1752127, encodeId=3ce11e5212757, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Sat Jul 20 11:57:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068592, encodeId=8fba206859295, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Apr 02 23:57:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030747, encodeId=003f2030e47c8, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Wed Oct 30 08:57:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365240, encodeId=36c43652400f, content=默默, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/23/fa6ad39852b3fd26b8f7093d53c322a1.jpg, createdBy=807b5083691, createdName=用户被禁用, createdTime=Thu Apr 25 15:59:35 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365202, encodeId=27ea365202b6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Apr 24 23:03:08 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369007, encodeId=5f3e136900e0d, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384693, encodeId=91271384693e6, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592165, encodeId=1e6f1592165a0, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Wed Apr 24 10:57:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365088, encodeId=44af3650882e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Apr 22 20:23:08 CST 2019, time=2019-04-22, status=1, ipAttribution=)]
    2019-04-22 orangesking

    好

    0

Baidu
map
Baidu
map
Baidu
map